Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers
NCT ID: NCT02594189
Last Updated: 2019-12-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
49 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-10-31
Study Completion Date
2017-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
Influenza A H3N2 is a flu virus. Symptoms include fever, cough, and runny nose. It can also be more serious. Researchers want to know more about how influenza causes disease in people. They hope to develop new vaccines and treatments for flu infection.
Objective:
To find the smallest amount of Influenza A H3N2 virus that causes a mild to moderate flu infection in healthy people. Also, to study the body s immune response to this virus and how the infection develops.
Eligibility:
Healthy people ages 18 50 who are:
Non-smokers or non-habitual smokers
Willing to not smoke for at least 9 days
Design:
Participants will be screened under NIAID protocol #11-I-0183
Participants will stay at an isolation unit at the clinic for at least 9 days. They will remain in the isolation unit except for study-specific activities.
The influenza virus will be sprayed into the nose.
Participants will be monitored 24 hours a day. They will have tests, including:
Medical history
Physical exam
Daily questionnaires about symptoms
Blood and urine tests
Nasal wash and swab: A small tube of salt water is placed in the nose to wash it. It then collects the
fluid. Or the inside of the nose is rubbed with a swab.
ECG: Measures the heart s electrical signals
ECHO: Sound waves take pictures of the heart
PFTs/Spirometry: They will blow into a machine that measures the air they blow.
Participants will be discharged after they test negative for influenza A.
Participants will return to the clinic for 4 follow-up visits over 8 weeks. They may complete questionnaires at home.
Influenza A H3N2 is a flu virus. Symptoms include fever, cough, and runny nose. It can also be more serious. Researchers want to know more about how influenza causes disease in people. They hope to develop new vaccines and treatments for flu infection.
Objective:
To find the smallest amount of Influenza A H3N2 virus that causes a mild to moderate flu infection in healthy people. Also, to study the body s immune response to this virus and how the infection develops.
Eligibility:
Healthy people ages 18 50 who are:
Non-smokers or non-habitual smokers
Willing to not smoke for at least 9 days
Design:
Participants will be screened under NIAID protocol #11-I-0183
Participants will stay at an isolation unit at the clinic for at least 9 days. They will remain in the isolation unit except for study-specific activities.
The influenza virus will be sprayed into the nose.
Participants will be monitored 24 hours a day. They will have tests, including:
Medical history
Physical exam
Daily questionnaires about symptoms
Blood and urine tests
Nasal wash and swab: A small tube of salt water is placed in the nose to wash it. It then collects the
fluid. Or the inside of the nose is rubbed with a swab.
ECG: Measures the heart s electrical signals
ECHO: Sound waves take pictures of the heart
PFTs/Spirometry: They will blow into a machine that measures the air they blow.
Participants will be discharged after they test negative for influenza A.
Participants will return to the clinic for 4 follow-up visits over 8 weeks. They may complete questionnaires at home.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influenza Human Challenge Model
NCT05332899
Influenza
RECRUITING
PHASE1
Influenza A 2009 H1N1 Challenge Study in Healthy Adults
NCT01646138
Influenza
COMPLETED
PHASE1/PHASE2
Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model
NCT05436444
Influenza Infection
COMPLETED
PHASE1
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
NCT02014870
Influenza A
COMPLETED
PHASE1
Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza
NCT07215871
Influenza Infection
Infections
Respiratory Virus Infections
+4 more
NOT_YET_RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The high morbidity and mortality associated with both pandemic and seasonal influenza, and the anticipation of future influenza pandemics, puts influenza front and center in infectious disease research. Because the natural history and pathogenesis of human influenza has not been well characterized and cannot be adequately studied in animal models or with current in vitro techniques, important questions about influenza pathogenesis can only be approached through human challenge studies.
Although studies of influenza in healthy volunteers have played an important role in addressing aspects of the natural history of influenza disease and developing novel antivirals, prior to recently these important studies had not been performed in the US in over a decade. The H1N1 challenge studies we have performed since 2012 have sought to improve upon the studies done in the past and address many of the limitations due to the scope of the studies and/or the scientific techniques available at that time. We have successfully developed an H1N1 model that had been used to address important questions regarding correlates of protection and is now being implemented to develop new drugs and vaccines. We hope to develop H3N2 models that can be just as useful.
The primary objective of this study is to determine the dose of influenza A H3N2 human challenge virus that will induce a mild to moderate uncomplicated influenza infection in healthy volunteers. This protocol will examine some of the basic questions that remain unanswered regarding the pathogenesis of H3N2 influenza in humans, namely, a detailed clinical and immunological characterization of uncomplicated influenza viral pathogenesis in healthy adult volunteers.
Secondary objectives will evaluate clinical disease, length of viral shedding, and pathogenesis in those with influenza infection including identification of clinical markers of the disease. Notably, the exploratory objectives will seek to discover viral factors necessary for human infection/adaptation and to evaluate host immune response, viral replication, viral fitness, and the intrahost evolution.
Collaboration between NIAID investigators and outside scientists will generate opportunities to further develop and expand areas of clinical influenza research based on the proposed H3N2 challenge model.
Although studies of influenza in healthy volunteers have played an important role in addressing aspects of the natural history of influenza disease and developing novel antivirals, prior to recently these important studies had not been performed in the US in over a decade. The H1N1 challenge studies we have performed since 2012 have sought to improve upon the studies done in the past and address many of the limitations due to the scope of the studies and/or the scientific techniques available at that time. We have successfully developed an H1N1 model that had been used to address important questions regarding correlates of protection and is now being implemented to develop new drugs and vaccines. We hope to develop H3N2 models that can be just as useful.
The primary objective of this study is to determine the dose of influenza A H3N2 human challenge virus that will induce a mild to moderate uncomplicated influenza infection in healthy volunteers. This protocol will examine some of the basic questions that remain unanswered regarding the pathogenesis of H3N2 influenza in humans, namely, a detailed clinical and immunological characterization of uncomplicated influenza viral pathogenesis in healthy adult volunteers.
Secondary objectives will evaluate clinical disease, length of viral shedding, and pathogenesis in those with influenza infection including identification of clinical markers of the disease. Notably, the exploratory objectives will seek to discover viral factors necessary for human infection/adaptation and to evaluate host immune response, viral replication, viral fitness, and the intrahost evolution.
Collaboration between NIAID investigators and outside scientists will generate opportunities to further develop and expand areas of clinical influenza research based on the proposed H3N2 challenge model.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
Group Type
OTHER
Live recombinantly derived A/Bethesda/MM1/H3N2 virus
Intervention Type
OTHER
The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Live recombinantly derived A/Bethesda/MM1/H3N2 virus
The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Greater than or equal to 18 and less than or equal to 50 years of age.
2. Agrees to not use tobacco products during participation in this study.
3. Willingness to remain in isolation for the duration of viral shedding (at a minimum 9 days) and to comply with all study requirements.
4. A female participant is eligible for this study if she is not pregnant or breastfeeding and meets 1 of the following criteria:
* Of nonchildbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in more than or equal to 1 year).
* Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks prior to and 8 weeks after administration of the influenza challenge virus. Acceptable methods of contraception include 1 or more of the following: 1) male partner who is sterile prior to the female participant s entry into the study and is the sole sexual partner for the female participant; 2) implants of levonorgestrel; 3) injectable progestogen; 4) an intrauterine device with a documented failure rate of \<1%; 5) oral contraceptives; and 6) double barrier methods including diaphragm or condom with a spermicide.
5. Willing to have samples stored for future research.
6. Pre-challenge serum hemaglutination-inhibition titer against the challenge strain of less than 1:40.
7. HIV uninfected.
2. Agrees to not use tobacco products during participation in this study.
3. Willingness to remain in isolation for the duration of viral shedding (at a minimum 9 days) and to comply with all study requirements.
4. A female participant is eligible for this study if she is not pregnant or breastfeeding and meets 1 of the following criteria:
* Of nonchildbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in more than or equal to 1 year).
* Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks prior to and 8 weeks after administration of the influenza challenge virus. Acceptable methods of contraception include 1 or more of the following: 1) male partner who is sterile prior to the female participant s entry into the study and is the sole sexual partner for the female participant; 2) implants of levonorgestrel; 3) injectable progestogen; 4) an intrauterine device with a documented failure rate of \<1%; 5) oral contraceptives; and 6) double barrier methods including diaphragm or condom with a spermicide.
5. Willing to have samples stored for future research.
6. Pre-challenge serum hemaglutination-inhibition titer against the challenge strain of less than 1:40.
7. HIV uninfected.
Exclusion Criteria
1. Presence of self-reported or medically documented significant medical condition including but not limited to:
1. Chronic pulmonary disease (e.g., asthma, emphysema).
2. Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure, cardiac surgery, ischemic heart disease, known anatomic defects).
3. Chronic medical conditions requiring close medical follow-up or hospitalization during the past 5 years (e.g., insulin-dependent diabetes mellitus, renal dysfunction, hemoglobinopathies).
4. Immunosuppression or ongoing malignancy.
5. Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures).
6. Post infectious or post vaccine neurological sequelae.
2. Have close or household (i.e., share the same apartment or house) high-risk contacts including but not limited to:
1. Persons more than or equal to 65 years of age.
2. Children less than or equal to 5 years of age.
3. Residents of nursing homes.
4. Persons of any age with significant chronic medical conditions such as:
* Chronic pulmonary disease (e.g., asthma).
* Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure, cardiac surgery, ischemic heart disease, known anatomic defects).
* Contacts who required medical follow-up or hospitalization during the past 5 years because of chronic medical conditions (e.g., insulindependent diabetes mellitus, renal dysfunction, hemoglobinopathies).
* Immunosuppression or cancer.
* Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures).
* Persons who are receiving long-term aspirin therapy.
* Women who are pregnant, trying to become pregnant, or breastfeeding.
3. Individual with body mass index (BMI) less than or equal to 18.5 and more than 40.
4. Smokes more than 4 cigarettes or other tobacco products on weekly basis.
5. Complete blood count (CBC) with differential outside of the NIH DLM normal reference range and deemed clinically significant by the PI.
6. Chemistries in the acute care, mineral, and/or hepatic panels, and/or any of the following: lactate dehydrogenase, uric acid, creatine kinase, and total protein outside of the NIH DLM normal reference range and deemed clinically significant by the PI.
7. Urinalysis outside of the NIH DLM normal reference range and deemed clinically significant by the PI.
8. Clinically significant abnormality as deemed by the PI on electrocardiogram (EKG)
9. Clinically significant abnormality as deemed by the PI on echocardiographic testing (ECHO).
10. Clinically significant abnormality as deemed by the PI on the Pulmonary Function Test (PFT).
11. Recent acute illness within 1 week of admission to the isolation facility.
12. Known allergy to treatments for influenza (including but not limited to oseltamivir, nonsteroidals).
13. Known allergy to 2 or more classes of antibiotics (e.g., penicillins, cephalosporins, fluoroquinolones, or glycopeptides).
14. Receipt of blood or blood products (including immunoglobulins) within 3 months prior to enrollment.
15. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) prior to enrollment.
16. Receipt of any unlicensed vaccine within 6 months prior to enrollment.
17. Self-reported or known history of current alcoholism or drug abuse, or positive urine/serum test for drugs of abuse (i.e., amphetamines, cocaine, benzodiazepines, opiates, or metabolites, but not THC or metabolites).
18. Self-reported or known history of psychiatric or psychological issues deemed by the PI to be a contraindication to protocol participation
19. Known close contact with anyone known to have influenza in the past 7 days.
20. Any condition that, in the judgment of the PI, is a contraindication to protocol participation or impairs the volunteer s ability to give informed consent.
1. Chronic pulmonary disease (e.g., asthma, emphysema).
2. Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure, cardiac surgery, ischemic heart disease, known anatomic defects).
3. Chronic medical conditions requiring close medical follow-up or hospitalization during the past 5 years (e.g., insulin-dependent diabetes mellitus, renal dysfunction, hemoglobinopathies).
4. Immunosuppression or ongoing malignancy.
5. Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures).
6. Post infectious or post vaccine neurological sequelae.
2. Have close or household (i.e., share the same apartment or house) high-risk contacts including but not limited to:
1. Persons more than or equal to 65 years of age.
2. Children less than or equal to 5 years of age.
3. Residents of nursing homes.
4. Persons of any age with significant chronic medical conditions such as:
* Chronic pulmonary disease (e.g., asthma).
* Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure, cardiac surgery, ischemic heart disease, known anatomic defects).
* Contacts who required medical follow-up or hospitalization during the past 5 years because of chronic medical conditions (e.g., insulindependent diabetes mellitus, renal dysfunction, hemoglobinopathies).
* Immunosuppression or cancer.
* Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures).
* Persons who are receiving long-term aspirin therapy.
* Women who are pregnant, trying to become pregnant, or breastfeeding.
3. Individual with body mass index (BMI) less than or equal to 18.5 and more than 40.
4. Smokes more than 4 cigarettes or other tobacco products on weekly basis.
5. Complete blood count (CBC) with differential outside of the NIH DLM normal reference range and deemed clinically significant by the PI.
6. Chemistries in the acute care, mineral, and/or hepatic panels, and/or any of the following: lactate dehydrogenase, uric acid, creatine kinase, and total protein outside of the NIH DLM normal reference range and deemed clinically significant by the PI.
7. Urinalysis outside of the NIH DLM normal reference range and deemed clinically significant by the PI.
8. Clinically significant abnormality as deemed by the PI on electrocardiogram (EKG)
9. Clinically significant abnormality as deemed by the PI on echocardiographic testing (ECHO).
10. Clinically significant abnormality as deemed by the PI on the Pulmonary Function Test (PFT).
11. Recent acute illness within 1 week of admission to the isolation facility.
12. Known allergy to treatments for influenza (including but not limited to oseltamivir, nonsteroidals).
13. Known allergy to 2 or more classes of antibiotics (e.g., penicillins, cephalosporins, fluoroquinolones, or glycopeptides).
14. Receipt of blood or blood products (including immunoglobulins) within 3 months prior to enrollment.
15. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) prior to enrollment.
16. Receipt of any unlicensed vaccine within 6 months prior to enrollment.
17. Self-reported or known history of current alcoholism or drug abuse, or positive urine/serum test for drugs of abuse (i.e., amphetamines, cocaine, benzodiazepines, opiates, or metabolites, but not THC or metabolites).
18. Self-reported or known history of psychiatric or psychological issues deemed by the PI to be a contraindication to protocol participation
19. Known close contact with anyone known to have influenza in the past 7 days.
20. Any condition that, in the judgment of the PI, is a contraindication to protocol participation or impairs the volunteer s ability to give informed consent.
Minimum Eligible Age
18 Years
Maximum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew J Memoli, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008 Apr 1;167(7):775-85. doi: 10.1093/aje/kwm375. Epub 2008 Jan 29.
Reference Type
BACKGROUND
Anderson MJ, Heath RB. Cell mediated immunity in experimental influenza and parainfluenza infection. Dev Biol Stand. 1977 Jun 1-3;39:379-83.
Reference Type
BACKGROUND
Brown TA, Murphy BR, Radl J, Haaijman JJ, Mestecky J. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol. 1985 Aug;22(2):259-64. doi: 10.1128/jcm.22.2.259-264.1985.
Reference Type
BACKGROUND
Han A, Czajkowski LM, Donaldson A, Baus HA, Reed SM, Athota RS, Bristol T, Rosas LA, Cervantes-Medina A, Taubenberger JK, Memoli MJ. A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model. Clin Infect Dis. 2019 Nov 27;69(12):2082-2090. doi: 10.1093/cid/ciz141.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-I-0008
Identifier Type: -
Identifier Source: secondary_id
160008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
NCT02918006
COMPLETED
PHASE2
Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
NCT04978454
COMPLETED
PHASE1
Human Infection Study of H3N2 Influenza in Healthy Adults
NCT06972810
ACTIVE_NOT_RECRUITING
NA
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
NCT00722774
COMPLETED
PHASE1
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
NCT06613737
COMPLETED
NA
Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers
NCT02822105
COMPLETED
PHASE1
A/Texas Flu Challenge
NCT06753474
RECRUITING
PHASE1
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
NCT00783926
COMPLETED
PHASE1
Influenza Challenge Study in Healthy Volunteers
NCT02746211
COMPLETED
PHASE1/PHASE2
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
NCT01730144
COMPLETED
H7N9 Boost in Healthy Adults
NCT02586792
COMPLETED
PHASE2
Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
NCT02525055
COMPLETED
NA
Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine
NCT00311727
COMPLETED
NA
Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine
NCT01443663
COMPLETED
PHASE1
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
NCT05875961
COMPLETED
PHASE1
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines
NCT00478816
COMPLETED
PHASE2
H1N1v Virus Challenge Study in Healthy Subjects
NCT04044352
COMPLETED
PHASE1
A/H5N1in Adult - Aventis
NCT00115986
COMPLETED
PHASE1/PHASE2
Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
NCT00264576
COMPLETED
PHASE2
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
NCT00922259
COMPLETED
PHASE1
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2
NCT01596725
COMPLETED
PHASE1
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)
NCT01910519
COMPLETED
PHASE2
Inactivated Influenza Via Jet Injection
NCT02290691
COMPLETED
PHASE4
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
NCT01320696
COMPLETED
PHASE1/PHASE2
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
NCT02385123
TERMINATED
PHASE4